Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial.
The Lancet Haematology.
Times cited: 4
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: A multicentre, randomised, dose-escalation phase 1 study.
The Lancet Oncology.
Times cited: 140
Genetic heterogeneity of diffuse large B-cell lymphoma.
Proceedings of the National Academy of Sciences of the United States of America.
Times cited: 299